Literature DB >> 30641663

[The clinical application of ventriculovesical shunts].

P Y Lou1, H Chen, Z H Wu, B Wang.   

Abstract

Objective: To report a clinical protocol for the application of ventriculovesical shunts (VV shunts) in patient who may be unable to maintain or receive ventriculoperitoneal (VP) shunts.
Methods: 25 patients underwent placement of VV shunts as an alternative to VP shunt therapy from March 2010 through March 2016. They all have malfunction of the VP shunt for the following reasons: peritoneal fluid inclusion(11 cases), failure of the peritoneum to absorb cerebrospinal fluid(7 cases), intra-abdominal infection(5 cases), peritoneal irritation pain(2 cases). The patients ranged in age from 5 years to 68 years old. All the patients underwent preoperative examine including urine routines, renal function electrolyte examination, imaging of the urinary bladder by ultrasonography.
Results: Two patients died from other diseases, one patient's shunts were removed due to proximal catheter occlusion 2 years after the operation, the penis pain was occurred in one patient. The rest patients had functional VV shunts. Conclusions: Ventriculovesical shunts may be considered for the treatment of hydrocephalus when the peritoneal cavity cannot be used as a distal terminus.

Entities:  

Keywords:  Hydrocephalus; Ventriculoperitoneal shunts; Ventriculovesical shunts

Mesh:

Year:  2019        PMID: 30641663     DOI: 10.3760/cma.j.issn.0376-2491.2019.01.009

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  2 in total

Review 1.  Ventriculorenal shunts in the treatment of pediatric and adult hydrocephalus-historical perspective and analysis of current practice.

Authors:  Cezar Octavian Morosanu; Adelina Priscu; Razvan George Rahota; Ioan Stefan Florian
Journal:  Childs Nerv Syst       Date:  2022-10-20       Impact factor: 1.532

Review 2.  Thrombosis associated with ventriculoatrial shunts.

Authors:  Dengjun Wu; Zhengyan Guan; Limin Xiao; Donghai Li
Journal:  Neurosurg Rev       Date:  2021-10-13       Impact factor: 3.042

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.